Tuberculosis resistance acquisition in space and time: an analysis of globally diverse M. tuberculosis whole genome sequences

Yasha Ektefaie, Avika Dixit, Luca Freschi, Maha FarhatbioRxiv 2019 · DOI

TL;DR

This study uses whole-genome sequencing and molecular dating to reconstruct the history of drug resistance in Mycobacterium tuberculosis (TB) across the globe. It reveals a consistent order of resistance acquisition and highlights that while transmission is a major driver of drug-resistant TB, the age of resistance acquisition varies significantly by country, correlating with wealth and suggesting a role for public health interventions.

What Problem Does This Paper Address?

Tuberculosis (TB) remains a significant global health challenge, exacerbated by the emergence and spread of drug-resistant strains (MDR-TB and XDR-TB). While we know that drug resistance varies geographically, the specific local factors driving its evolution and persistence have been poorly understood. This paper aims to fill this gap by investigating when and where drug resistance emerged and spread across diverse TB populations worldwide, providing insights into the dynamics of resistance acquisition and transmission.

Methods

The researchers employed a multi-pronged approach:

  • Data Curation: They compiled a large dataset of over 10,000 M. tuberculosis whole-genome sequences (WGS) with associated drug susceptibility testing (DST) data from numerous countries.
  • Phylogenetic Analysis: Using WGS data, they constructed phylogenetic trees to understand the evolutionary relationships between different TB isolates.
  • Bayesian Molecular Dating: This is the core of their temporal analysis. They used Bayesian methods to estimate the "Most Recent Common Susceptible Ancestor" (MRSCA) age for resistance to various drugs. Essentially, this tells them how long ago a particular drug resistance mutation likely emerged in the TB lineage.
  • Correlation Analysis: They investigated the relationship between the age of resistance acquisition and socio-economic factors, specifically using Gross Domestic Product (GDP) per capita as a proxy for TB control program funding and resources.
  • Diagnostic Sensitivity Assessment: They compared the performance of commercial diagnostic tests for second-line drug resistance across different countries.

Datasets

The study utilized a dataset of 10,299 M. tuberculosis clinical isolates with WGS and culture-based DST data. These isolates were sourced from over 20 countries, with 6,099 meeting the criteria for molecular dating analysis.

Key Insights and Ideas

  • A Consistent "Resistance Ladder": The study found a remarkably consistent order in which TB strains acquire resistance globally: isoniazid resistance typically emerges first, followed by rifampicin and streptomycin, and then other drugs. This suggests a predictable evolutionary pathway for resistance.
  • Old Resistance, High Fitness: The presence of "old" resistance (dating back over 20 years) in many countries indicates that these resistant strains are not only surviving but are also fit for transmission and persistence in human hosts.
  • Wealth Matters for Resistance Age: A significant finding is the correlation between country wealth (GDP per capita) and the age of resistance. Wealthier nations tend to have older resistance, suggesting that better healthcare infrastructure and TB control programs might slow down the emergence of new resistance, even if older strains persist.
  • Diagnostic Disparities: Commercial diagnostic tests show significant variability in their sensitivity for detecting second-line drug resistance across different countries, highlighting a need for context-specific diagnostic strategies.

Key Results

  • Molecular Dating: They estimated MRSCA dates for 4,869 instances of resistance to 10 different drugs.
  • Transmission Burden: The analysis estimated that 14-52% of resistance could be attributed to ongoing transmission, with INH and RIF resistance being the most frequently transmitted.
  • Order of Resistance: The median MRSCA for INH resistance was 11.4 years prior to sample collection, significantly older than for RIF (7.6 years). EMB resistance followed RIF, and then PZA, ETH, FLQ, SLIs, or CYS.
  • Recent Amplification: Resistance to fluoroquinolones (FLQ) and second-line injectables (SLIs) among MDR isolates was estimated to have occurred very recently, with a median ancestral age of only 4.7 years.
  • GDP Correlation: A direct correlation was found between country wealth and resistance age (R²=0.47, P=0.014), with wealthier nations exhibiting older resistance.
  • Diagnostic Sensitivity: Commercial diagnostic sensitivity for second-line resistance varied significantly by country (P<0.0003).

Limitations and Future Work

  • Distinguishing Importation vs. Acquisition: The study acknowledges that its approach cannot definitively distinguish between resistance imported through human migration and new resistance acquired within a country. This means their estimates of transmission burden might be underestimates.
  • Oversampling of DR Isolates: The study's sample may have overrepresented drug-resistant isolates compared to the general TB population, as indicated by comparisons with WHO MDR rates.
  • Phylogenetic and Molecular Clock Assumptions: The accuracy of molecular dating relies on accurate phylogenetic tree estimation and molecular clock assumptions, which, while rigorously applied, are inherent to the method.
  • DST Accuracy: The analysis assumes the accuracy of culture-based phenotypic DST, acknowledging that test-to-test variability can exist.

Future work could focus on refining transmission estimates, developing more geographically tailored diagnostic tools, and further investigating the factors that contribute to the fitness and longevity of resistant TB strains. The authors also emphasize the importance of sharing systematically collected isolate data to enable future reassessments of these patterns.

Summary updated

Abstract

Abstract Background Mycobacterium tuberculosis (MTB) whole genome sequencing data can provide insights into temporal and geographic trends in resistance acquisition and inform public health interventions. Methods We curated a set of clinical MTB isolates with high quality sequencing and culture-based drug susceptibility data spanning four lineages and more than 20 countries. We constructed geographic and lineage specific MTB phylogenies and used Bayesian molecular dating to infer the most-recent-common-susceptible-ancestor age for 4,869 instances of resistance to 10 drugs. Findings Of 8,550 isolates curated, 6,099 from 15 countries met criteria for molecular dating. The number of independent resistance acquisition events was lower than the number of resistant isolates across all countries, suggesting ongoing transmission of drug resistance. Ancestral age distributions supported the presence of old resistance, ≥20 years prior, in the majority of countries. A consistent order of resistance acquisition was observed globally starting with resistance to isoniazid, but resistance ancestral age varied by country. We found a direct correlation between country wealth and resistance age ( R 2 = 0.47, P-value= 0.014). Amplification of fluoroquinolone and second-line injectable resistance among multidrug-resistant isolates is estimated to have occurred very recently (median ancestral age 4.7 years IQR 1.9-9.8 prior to sample collection). We found the sensitivity of commercial molecular diagnostics for second-line resistance to vary significantly by country (P-value &lt;0.0003) Interpretation Our results highlight that both resistance transmission and amplification are contributing to disease burden globally but are variable by country. The observation that wealthier nations are more likely to have old resistance suggests that programmatic improvements can reduce resistance amplification, but that fit resistant strains can circulate for decades subsequently. Funding This work was supported by the NIH BD2K grant K01 ES026835, a Harvard Institute of Global Health Burke Fellowship (MF), Boston Children’s Hospital OFD/BTREC/CTREC Faculty Career Development Fellowship and Bushrod H. Campbell and Adah F. Hall Charity Fund/Charles A. King Trust Postdoctoral Fellowship (AD). Research in context Evidence before this study Acquisition and spread of drug-resistance by Mycobacterium tuberculosis (MTB) varies across countries. Local factors driving evolution of drug resistance in MTB are not well studied. Added value of this study We applied molecular dating to 6,099 global MTB patient isolates and found the order of resistance acquisition to be consistent across the countries examined, i.e. acquisition of isoniazid resistance first followed by rifampicin and streptomycin followed by resistance to other drugs. In all countries with data available there was evidence for transmission of resistant strains from patient-to-patient and in the majority for extended periods of time (&gt;20 years). Countries with lower gross wealth indices were found to have more recent resistance acquisition to the drug rifampicin. Based on the resistance patterns identified in our study we estimate that commercial diagnostic tests vary considerably in sensitivity for second-line resistance diagnosis by country. Implications of all available evidence The longevity of resistant MTB in many parts of the world emphasizes its fitness for transmission and its continued threat to public health. The association between country wealth and recent resistance acquisition emphasizes the need for continued investment in TB care delivery and surveillance programs. Geographically relevant diagnostics that take into account a country’s unique distribution of resistance are necessary.
BibTeX
@misc{ektefaie2019tuberculosis,
  author = {Yasha Ektefaie and Avika Dixit and Luca Freschi and Maha Farhat},
  title = {{Tuberculosis resistance acquisition in space and time: an analysis of globally diverse <i>M. tuberculosis</i> whole genome sequences}},
  year = {2019},
  doi = {10.1101/837096},
  howpublished = {bioRxiv},
}
Figure